<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00005028</url>
  </required_header>
  <id_info>
    <org_study_id>MSGCC-9948</org_study_id>
    <secondary_id>CDR0000067549</secondary_id>
    <secondary_id>NCI-50</secondary_id>
    <nct_id>NCT00005028</nct_id>
  </id_info>
  <brief_title>Paclitaxel and Bryostatin 1 in Treating Patients With Metastatic Prostate Cancer</brief_title>
  <official_title>Phase II Study of Weekly Paclitaxel and Bryostatin-1 in Hormone Refractory Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Maryland, Baltimore</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Maryland, Baltimore</source>
  <brief_summary>
    <textblock>
      Phase II trial to study the effectiveness of combining paclitaxel and bryostatin 1 in&#xD;
      treating patients who have metastatic prostate cancer that has not responded to hormone&#xD;
      therapy. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die. Combining more than one drug may kill more tumor cells.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      I. Determine the onset, duration, and degree of response in patients with hormone-refractory,&#xD;
      metastatic adenocarcinoma of the prostate treated with paclitaxel and bryostatin 1.&#xD;
&#xD;
      II. Determine the toxicity of this regimen in these patients. III. Determine the overall&#xD;
      survival of patients treated with this regimen.&#xD;
&#xD;
      OUTLINE: This is an open-label, multicenter study.&#xD;
&#xD;
      Patients receive paclitaxel IV over 1 hour on days 1, 8, and 15 and bryostatin 1 IV over 1&#xD;
      hour on days 2, 9, and 16. Treatment repeats every 4 weeks in the absence of disease&#xD;
      progression or unacceptable toxicity.&#xD;
&#xD;
      Patients are followed monthly for 6 months and then every 3 months thereafter.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 2000</start_date>
  <completion_date type="Actual">July 2006</completion_date>
  <primary_completion_date type="Actual">July 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">46</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive paclitaxel IV over 1 hour on days 1, 8, and 15 and bryostatin 1 IV over 1 hour on days 2, 9, and 16. Treatment repeats every 4 weeks in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bryostatin 1</intervention_name>
    <arm_group_label>Arm I</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel</intervention_name>
    <arm_group_label>Arm I</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed metastatic adenocarcinoma of the prostate that failed first-&#xD;
             or second-line hormonal therapy (e.g., gonadal androgen suppression [orchiectomy or&#xD;
             luteinizing hormone-releasing hormone] with or without antiandrogens)&#xD;
&#xD;
               -  Failure on hormonal therapy is defined by 1 of the following criteria:&#xD;
&#xD;
                    -  Biochemical progression (after withdrawal of antiandrogens), documented by 3&#xD;
                       rising PSA values, each value measured at least 2 weeks apart, with the last&#xD;
                       measurement being at least 25% of the nadir achieved while on hormonal&#xD;
                       therapy and with an increase in the absolute value by at least 5 ng/mL&#xD;
&#xD;
                    -  Measurable disease progression, defined by an increase in the sum of the&#xD;
                       products of the perpendicular diameters of any measurable lesion(s) by at&#xD;
                       least 25%&#xD;
&#xD;
          -  Bone only progression allowed only with concurrent biochemical progression&#xD;
&#xD;
          -  Castrate levels of testosterone (no greater than 50 ng/dL)&#xD;
&#xD;
          -  No clinical signs/symptoms suggesting CNS metastases&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-1&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  More than 6 months&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  WBC at least 3,000/mm^3&#xD;
&#xD;
          -  Absolute granulocyte count at least 1,500/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin no greater than 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  AST/ALT no greater than 2.5 times ULN&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine no greater than 1.5 times ULN&#xD;
&#xD;
          -  Calcium no greater than ULN&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No uncontrolled or severe cardiovascular disease&#xD;
&#xD;
          -  No myocardial infarction within the past 6 months&#xD;
&#xD;
          -  No congestive heart failure&#xD;
&#xD;
          -  No angina pectoris&#xD;
&#xD;
          -  No active thromboembolic events within the past 3 months (e.g., deep venous thrombosis&#xD;
             or cerebrovascular accident)&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No other serious medical or psychiatric illness&#xD;
&#xD;
          -  No active infection&#xD;
&#xD;
          -  No dementia or significantly altered mental status&#xD;
&#xD;
          -  No prior or concurrent grade 1 or greater peripheral neuropathy&#xD;
&#xD;
          -  No other prior or concurrent malignancy within the past 5 years except curatively&#xD;
             treated nonmelanoma skin cancer&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  No prior chemotherapy (including paclitaxel)&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  At least 4 weeks since prior steroids or megestrol&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  At least 4 weeks since prior radiotherapy to bone lesions&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No other concurrent investigational therapy&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arif Hussain, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Maryland Greenebaum Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Greater Baltimore Medical Center and Cancer Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comprehensive Cancer Center at Wake Forest University</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157-1082</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fox Chase Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111-2497</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wellspan Health - York Cancer Center</name>
      <address>
        <city>York</city>
        <state>Pennsylvania</state>
        <zip>17403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>April 6, 2000</study_first_submitted>
  <study_first_submitted_qc>March 6, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 7, 2003</study_first_posted>
  <last_update_submitted>October 31, 2019</last_update_submitted>
  <last_update_submitted_qc>October 31, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adenocarcinoma of the prostate</keyword>
  <keyword>stage IV prostate cancer</keyword>
  <keyword>recurrent prostate cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Bryostatin 1</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

